蝴蝶网络 BFLY

Joseph DeVivo has served as our Chief Executive Officer and Chairperson of our board of directors since April 2023. Mr. DeVivo previously served as the President of Hospital and Health Systems for Teladoc Health, Inc. (Teladoc) (NYSE: TDOC), a telemedicine and virtual healthcare company, from July 2020 to April 2022. Mr. DeVivo was the Chief Executive Officer and Director of InTouch Health from 2016 until June 2020, when it was acquired by Teladoc. Prior to that, Mr. DeVivo served as the President, Chief Executive Officer and Director of Angiodynamics Inc. from 2011 to 2016. He is also currently a member of the Board of Directors of Quantum Surgical and is the Treasurer on the board of directors at the American Telemedicine Association and previously served as the Executive Chairman of the board of directors of Caption Health prior to Caption Health's acquisition by GE Healthcare in February 2023. Mr. DeVivo received his Bachelor of Science degree in Business Administration and Marketing and Management from the University of Richmond.

John Doherty brings 30 years of finance and operational expertise and is an accomplished executive with extensive experience in corporate development. He has served as our Chief Financial Officer since December 2025. In this capacity, Mr. Doherty oversees the company's financial strategy, capital allocation, and investor relations. Prior to joining Butterfly, Mr. Doherty served as Chief Financial Officer of Kaltura, Inc., a provider of live, real-time, and on-demand video offerings for enterprises, from March 2024 to December 2025. Prior to that, Mr. Doherty served as Chief Financial and Operating Officer for Magic Leap, Inc., an augmented reality technology company, from 2020 to 2024, and as Chief Financial Officer of InterXion Holding N.V., a data center services provider, from 2018 to 2020. In addition, Mr. Doherty held a variety of financial roles at Verizon Communications Inc., over a 30-year period, most recently serving as Senior Vice President of Corporate Development and President & Chief Investment Officer of Verizon Ventures from 2013 to 2018, where he helped steer significant strategic transactions and corporate restructurings. Mr. Doherty currently also serves on the Board of Directors of Guam-based Pacific Telecom, Inc. Mr. Doherty holds a degree in economics from Stony Brook University and has attended the MBA program at Baruch College as well as Wharton's Executive Education program in Finance and Strategic Planning.

Steven Cashman brings 25 years of sales and operational expertise and is an accomplished entrepreneur with extensive experience in healthcare. He has served as our Chief Business Officer since September 2024. In this capacity, Mr. Cashman oversees global sales, marketing, product and corporate strategy. Prior to joining Butterfly, from April 2021 to August 2023, Mr. Cashman was the President & CEO of Caption Health, a medical technology manufacturer, where he led the development and commercialization of the industry's first AI-powered ultrasound platform, culminating in its acquisition by GE Healthcare in February 2023. Before Caption Health, from January 2018 to August 2020, he served as Chief Commercial Officer at InTouch Health, where he was responsible for domestic and global growth, product development, marketing, customer service, and clinical services. In addition to his executive roles, Mr. Cashman is actively involved in the startup community as an angel investor and board member. He currently serves on the boards of Vista.ai, Sovato, and PatientGenie.

Larry Robbins has served on our board of directors since our inception and serves as our Lead Independent Director. Mr. Robbins served as our Chairman from inception to February 2021. Since November 2024, he has served on the board of directors of CVS Health Corporation (NYSE: CVS). Mr. Robbins is the Founder, Portfolio Manager and Chief Executive Officer of Glenview Capital Management (Glenview). Prior to founding Glenview in 2000, Mr. Robbins spent six years as an analyst and partner at Omega Advisors (Omega) on their U.S. equity long/short team. He joined Omega after three years at Gleacher & Company, a merger and acquisition advisory boutique in New York. Through their Robbins Family Foundation, Mr. Robbins and his wife Sarahmay are active supporters of education reform both in New York City and on a national level. He serves as Chairman of the board of directors for Array Education and the Knowledge Is Power Program (KIPP) New York, and he is a board member for the Relay Graduate School of Education, Robin Hood Foundation and Zearn. In addition, Mr. Robbins is the Senior Chair of the Wall Street Division of the UJA-Federation. Mr. Robbins graduated with honors from the Wharton School and Moore School of the University of Pennsylvania in 1992, where he received his B.S. in Economics and Engineering, with majors in accounting, finance, marketing, and systems engineering. Mr. Robbins is also a certified public accountant.

Dawn Carfora has served on our board of directors since the closing of the Business Combination in February 2021 and serves as the Chair of our compensation committee since 2024. Ms. Carfora previously served as Vice President, Business Planning and Operations, Global Business Group of Meta Platforms, Inc. (formerly Facebook, Inc.) (Meta) (Nasdaq: META) from September 2019 through December 2024. Prior to that, Ms. Carfora held a variety of senior leadership roles at Meta, including as Director, GMS Operations (Global Sales Operations) from October 2017 to September 2019 and as Director, Sales Operations, North America from March 2014 to October 2017. Ms. Carfora previously served as Chief Financial Officer of MagPlus Inc. from November 2013 to March 2014. Prior to MagPlus, from May 2007 to November 2013, she held various senior leadership positions at PDR Network, LLC (PDR). Before joining PDR, Ms. Carfora held various roles of increasing responsibility at MediZine Inc., Primedia Inc., Twentieth Century Fox Home Entertainment, Inc., Ernst & Young LLP and Bertelsmann SE & Co. Ms. Carfora received her B.S. in business administration, finance from Rider University.

Elazer Edelman, M.D., Ph.D. has served on our board of directors since March 2021 and serves as the Chair of our technology committee. Dr. Edelman has served as the Edward J. Poitras Professor in Medical Engineering and Science at the Massachusetts Institute of Technology which he joined in 1993, Professor of Medicine at Harvard Medical School which he joined in 1989, and Senior Attending Physician in the coronary care unit at the Brigham and Women's Hospital in Boston with which he has been associated since 1984. He and his laboratory have pioneered basic findings in vascular biology and the development and assessment of biotechnology. Dr. Edelman has directed the Massachusetts Institute of Technology's Institute for Medical Engineering and Science and Clinical Research Center as well as the Harvard-MIT Biomedical Engineering Center, all dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease. He is the founder and has served on the board of director of Autus Valve Technologies, Inc. since 2019, BioDevek, Inc. since 2015, and PanTher Therapeutics, LLC since 2014. Dr. Edelman completed internal medicine training and clinical fellowship in Cardiovascular Medicine at the Brigham and Women's Hospital and a research fellowship at the Department of Pathology at Harvard Medical School. Dr. Edelman received his M.D. from Harvard Medical School and his Ph.D. in Medical Engineering and Medical Physics, M.S. in Electrical Engineering and Computer Science, and B.S. in Bioelectrical Engineering and Applied Biology from the Massachusetts Institute of Technology.

On September 29, 2026, the Board of Directors of Butterfly Network, Inc. appointed Michael Noonen to the Board, effective on October 9, 2026. Mr. Noonen is a seasoned semiconductor executive with 30 years of experience leading technology businesses, resulting in two IPOs and multiple acquisitions. He most recently served as CEO of Swave Photonics, a fabless semiconductor company developing holographic chips. Previously, he was CEO of MixComm, a 5G and satellite communications semiconductor company acquired by Sivers Semiconductors in 2022. Earlier in his career, Mr. Noonen held senior global leadership roles at two of the industry's largest semiconductor companies. He served as Executive Vice President of Global Products, Design, Sales and Marketing at GlobalFoundries, and as Executive Vice President of Worldwide Sales and Marketing at NXP Semiconductors. He is also the co-founder and former Chairman of Silicon Catalyst, the world's first semiconductor-focused incubator, named EE Times Start-Up of the Year in 2015. In 2013, he was elected to the Global Semiconductor Alliance Board of Directors. Mr. Noonen holds a Bachelor of Science in Electrical Engineering from Colorado State University, which named him its College of Engineering Distinguished Alumnus of the Year in 2012.

Caroll H. Neubauer has served as an executive advisor at Water Street Healthcare Partners, LLC, a financial consultant, since October 2020. Prior to that, Mr. Neubauer worked for the B. Braun Group, a medical and pharmaceutical device company (B. Braun), including serving on the Global Management Board of the B. Braun SE / B. Braun Melsungen AG from 1991 until 2020. Mr. Neubauer also led B. Braun's North American operations, serving as Chairman and CEO of B. Braun of America Inc., a premier provider of infusion therapy and pain management solutions, from 1996 until 2020. In addition, Mr. Neubauer has served on the board of directors for The Advanced Medical Technology Association (AdvaMed), where he worked with other industry leaders to spearhead the initiative that successfully repealed the U.S. medical device tax in 2019. AdvaMed recognized Mr. Neubauer with a Lifetime Achievement Award in 2024. Mr. Neubauer also served as Chairman of the German American Chamber of Commerce New York from 2008 until 2019, initiating programs to benefit transatlantic relations and healthcare communities in the United States and Europe. Mr. Neubauer earned a German Law degree from The Albert Ludwigs University, Freiburg, Germany, and a Master of Laws from Georgetown University. Mr. Neubauer's qualifications to serve on our board of directors include his extensive leadership experience in medical device companies and his background in law, further bolstered by his recent governance roles as a member of the Supervisory Board of Zimmer MedizinSystems GmbH from 2021 until 2025, current Chairman of the Board of iRen Medical Ltd. since 2022, and a member of the Board of GlobalMed Logistix, LLC since 2026.

Victor Ku brings more than two decades of leadership expertise in advancing semiconductor-based imaging, AI-enabled analytics, and complex sensing systems. He has served as our Chief Technology Officer since September 2025. In this capacity, Dr. Ku leads Butterfly's global technology strategy, product development, and innovation roadmap. Prior to joining Butterfly, Dr. Ku served as Vice President of R&D, Engineering, and PMO at Headwall Photonics, a PE-backed company, where he led global teams developing hyperspectral imaging systems for industrial and machine-vision applications. His previous leadership roles include senior engineering positions at Teledyne FLIR, onsemi, and IBM, where he oversaw full-stack product platforms